Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors

Kiyohiro Ando, Kazuyuki Hamada, Makoto Watanabe, +13

Anticancer Research

Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy

Kazuyuki Hamada, Kiyoshi Yoshimura, Yuya Hirasawa, +20

Anticancer Research

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor

Kazuyuki Hamada, Junya Isobe, Kouya Hattori, +25

Frontiers in Immunology

Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies

Ryotaro Ohkuma, Katsuaki Ieguchi, Makoto Watanabe, +16

Biomedicines

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Masakazu Murayama, Masahiro Hosonuma, Atsuo Kuramasu, +30

Scientific Reports

A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors

Kiyohiro Ando, Kazuyuki Hamada, Midori Shida, +14

Cancer Immunology Immunotherapy

Pd-l1+ Cd14+Cancer ImmunosurveillanceAutoimmune DiseaseHematologyImmunology +7

High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer

Ryotaro Ohkuma, Erica Yada, Shumpei Ishikawa, +26

PLoS ONE

Tumor BiologyPancreatic CancerTumor HeterogeneityMedicineHigh Expression +10

A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy

Yuya Hirasawa, Kiyoshi Yoshimura, Hiroto Matsui, +23

Medicine

High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer

Ryotaro Ohkuma, Erica Yada, Shumpei Ishikawa, +22

Oncology Reports

ImmunologyPathologyImmunotherapeuticsHigh Expression LevelsImmunotherapy +16

Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil

Masae Sekido, Ken‐ichi Fujita, Yutaro Kubota, +7

Cancer Chemotherapy and Pharmacology

Drug SafetyPharmacological StudyPharmacologySystemic ExposureClinical Pharmacology +7